Announcement approximately success of solanezumab leads to calls for improved testing to identify those who would benefit from slowing of mental declineMajor improvements must be made in techniques for identifying future Alzheimer’s disease patients if medicine is to recall advantage of drugs that could inhibit (restrain; prohibit; retard or prevent) or halt their mental decline.
This warning was made last week by several senior scientists after the announcement by the pharmaceutical giant Eli Lilly that its drug,solanezumab, had been shown to stave off memory loss in patients with gentle Alzheimer’s.
Continue reading...
Source: theguardian.com